BioSpace News Archive

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative has awarded $75,000 to David E. Avigan, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School for the development of a personalized dendritic cell/organoid-based vaccine for the treatment of gastric cancer.

Theradaptive, the market leader in targeted regenerative therapeutics, has gained approval from the U.S. Food and Drug Administration (FDA) for their Investigational Device Exemption (IDE) submission to begin enrolling patients into OASIS, their global Phase I/II Feasibility study in spine fusion.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that it will present at the 20th Annual WORLDSymposium™ being held February 4-9, 2024, in San Diego, California.

Omeros Corporation announced the sale to DRI Healthcare Acquisitions LP, a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.

Co-Diagnostics, Inc. announced the list of events it has chosen to exhibit at or participate in during February, 2024, and which strategically align with the Company’s vision.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapeutics

Madison Wisconsin based Imbed Biosciences, Inc has been awarded a Technology Breakthrough designation for PelashieldAM ™ with Premier, Inc. performance group and collaborative.

Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024.